According to the source, Indian drug developer Lupin Ltd. confirmed that it has settled a patent dispute with Schering-Plough Corp. over that company's allergy drug Desloratidine; Clarinex®.
Under the settlement, Lupin said it would be able to sell a generic version of the drug starting July 1, 2012. The company did not provide further detail on the settlement. The deal means that Lupin would be able to sell a generic version of the drug before the key patent (US 6100274) expires in January of 2020. Lupin had previously asked for regulatory approval of a generic version, triggering a lawsuit by Schering-Plough.
No comments:
Post a Comment